ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA

抗 C20 IDEC C2B8（利妥昔单抗）治疗艾滋病相关非霍奇金淋巴瘤

• 批准号: 6302997
• 负责人: MANSOOR N SALEH
• 金额: $ 2.95万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6302997
• 关键词: AIDS related neoplasm /cancer; AIDS therapy; antineoplastics; clinical research; drug screening /evaluation; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; nonHodgkin's lymphoma; virus load

To date 2 patients with signs of associated aggressive non-Hodgkin's lymphoma have been treated on study. Patient #1 completed 8 cycles Patient #2 died of progressive disease following the first treatment (3 cycles) Patient #1 achieved a PR. No increase in infectious complications or opportunistic infections were observed in this study.

迄今为止，2例具有相关侵袭性非霍奇金淋巴瘤体征的患者在研究中接受了治疗。患者#1完成了8个周期，患者#2在第一次治疗（3个周期）后死于疾病进展。患者#1达到PR。在本研究中未观察到感染并发症或机会性感染增加。